Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
Rhea-AI Summary
Evotec (NASDAQ:EVO) will report fourth-quarter and full-year 2025 results and provide a business update via webcast and conference call on April 8, 2026.
The live webcast starts at 2:00 pm CEST (8:00 am EDT); registration is required to access the audio, presentation slides, and dial-in details. An on-demand replay will be available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – EVO
In the Apr 1 session, EVO gained 1.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Government funding deal | Positive | -2.1% | BARDA consortium award up to $10m for Ebola antibody manufacturing. |
| Mar 19 | Collaboration milestone | Positive | +0.4% | BMS-986506 Phase 1 start triggers $10m milestone from BMS collaboration. |
| Jan 08 | AI grant award | Positive | +1.4% | Gates Foundation grant funds ten AI-driven J.MD projects over three years. |
| Jan 02 | Leadership appointment | Positive | +3.3% | Appointment of Dr. Sarah Fakih as EVP, Global Communications and IR. |
| Dec 08 | Asset sale to Sandoz | Positive | -3.5% | Closing Toulouse site sale with potential >US$650m plus biosimilar royalties. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has been mostly positive, but price reactions have been mixed, with notable selloffs on some large strategic deals.
Over the last six months, Evotec reported several positive developments, including BARDA-backed Ebola manufacturing work worth up to $10 million, a $10 million Bristol Myers Squibb milestone on a Phase 1 study, and a Gates Foundation AI grant funding ten J.MD™ projects over three years. It also closed the Toulouse site sale to Sandoz with potential payments above US$650m. Despite these, share reactions have alternated between gains and pullbacks, framing the upcoming April 8, 2026 earnings call within a volatile trajectory.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.
Webcast details
Date: Wednesday, April 8, 2026
Time: 2.00 pm CEST (12.00 pm GMT, 8.00 am EDT)
To join the audio webcast and to access the presentation slides, please register via this link.
The on-demand version of the webcast will be available on our website: www.evotec.com.
Conference call details
To join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire